Search
Search
Close this search box.

Eau my! Another cannabis trademark lawsuit

The makers of Cointreau, the French triple sec orange-flavoured liqueur, filed a lawsuit against Canopy Growth for its Quatreau CBD drink brand name for what they perceive is an effort “unfairly capitalize on the goodwill and reputation of the COINTREAU Mark,” according to the complaint.

(This is the second cannabis brand-related lawsuit this week to make headlines: Sacha Baron Cohen sues cannabis company.)



What’s in a name?

The issue is not as much about the look of the name Quatreau, and more about the way it is pronounced — like kwatro — and liqueur brand’s potential plans to create ready-to-drink bevvies of their own. Consumers could, the lawsuit argues, confuse Quatreau with Cointreau.

“They have done so knowing full well that Cointreau (pronounced kwantro) with only the ‘n’ sound differentiating it … is frequently used for mixed drinks featuring sodas and waters, and which plaintiffs could reasonably be expected by consumers to expand to flavoured waters, sodas, and ready-to-drink cocktails, as evidenced by plaintiffs’ recent US trademark registration.” 

But is it really Cointreau if it isn’t from France’s Cointreau region?

Cointreau has a few demands listed in the lawsuit, reports Marijuana Business Daily. They want a court order against Canopy’s trademark applications in the US to use Quatreau, for Canopy to not be allowed to sell Quatreau products and a ruling that they “infringed and diluted” on Cointreau’s trademark.

Competition heating up

It’s a lawsuit worth consideration by even seasoned beverage makers entering the weed drink space — most recently Jones Soda and Dale’s Pale Ale. And the competition is only getting fiercer — drinks are selling briskly in the mature California market — sales increased from $67.8 million to $95.2 million from 2019 to 2020.

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?